JAMA Cardiology

MARCH 11, 2025

This randomized clinical trial evaluates if HU6, a controlled metabolic accelerator, reduces body weight, improves body composition, and increases exercise capacity in patients with obesity-related heart failure with preserved ejection fraction (HFpEF).

Preserved Ejection Fraction 71

Preserved Ejection Fraction Obesity Heart Failure Exercise 71

European Journal of Heart Failure

DECEMBER 7, 2023

Increasing severity of obesity is associated with multiple characteristics that may contribute to the development or worsening of heart failure (HF) with preserved ejection fraction (HFpEF). Echocardiography demonstrated increased CO with obesity, but not estimated right atrial (RA) pressure or E/e′.

Preserved Ejection Fraction 40

Preserved Ejection Fraction Obesity Heart Failure BMI 40

Circulation

JANUARY 22, 2025

Optimal NT-proBNP cut points for HFpEF rule out (optimizing sensitivity) and rule in (optimizing specificity) were derived and tested, stratified by obesity and atrial fibrillation. In our study, NT-proBNP provided little value in those with AF and dyspnea because the presence of AF is by itself a robust biomarker of HFpEF.

Preserved Ejection Fraction 55

Preserved Ejection Fraction Outpatient Heart Failure BMI 55

Circulation: Heart Failure

SEPTEMBER 12, 2023

BACKGROUND:Obesity and adiposity are associated with an increased risk of heart failure with preserved ejection fraction (HFpEF); yet, specific underlying mechanisms remain unclear. We defined HFpEF based on the presence of elevated left ventricular filling pressures at rest or during exercise. P<0.001).

Biomarkers 40

Biomarkers Obesity Exercise Preserved Ejection Fraction 40

Journal of the American Heart Association

FEBRUARY 14, 2024

Pathological increases in renal sympathetic nerve activity contribute to the pathogenesis of heart failure with preserved ejection fraction (HFpEF).We Pathological increases in renal sympathetic nerve activity contribute to the pathogenesis of heart failure with preserved ejection fraction (HFpEF).We

Preserved Ejection Fraction 40

Preserved Ejection Fraction Heart Failure Blood Pressure Biomarkers 40

Circulation

NOVEMBER 11, 2024

Intro:Drug Development for Heart failure with Preserved Ejection Fraction (HFpEF) is a major challenge facing cardiovascular research due to its complex pathophysiology and existence of comorbidities, leading to recognize distinct HFpEF phenogroups. HFD/L-NAME mice showed altered exercise capacity (p<0.05

Hypertension 40

Hypertension Preserved Ejection Fraction Blood Pressure Obesity 40

DAIC

FEBRUARY 29, 2024

ET Murphy Ballroom 4 Comparison of an "Inclisiran First" Strategy with Usual Care in Patients With Atherosclerotic Cardiovascular Disease: Results From the VICTORION-INITIATE Randomized Trial Targeting Weight Loss to Personalize the Prevention of Type 2 Diabetes Once-weekly Semaglutide in Patients with Heart Failure With Preserved Ejection Fraction, (..)

Aortic valve 103

Aortic valve Myocardial Infarction Aortic Blood Pressure 103